Frontiers in ImmunologyBackgroundImmune checkpoint inhibitors have revolutionized cancer therapy, but many patients fail to respond or develop resistance, often due to reduced T cell activity.
Oana Hangiu +27 more
doaj +1 more source
Modeling the mechanisms of antibody mixtures in viral infections: the cases of sequential homologous and heterologous dengue infections [PDF]
arXivAntibodies play an essential role in the immune response to viral infections, vaccination, or antibody therapy. Nevertheless, they can be either protective or harmful during the immune response. Moreover, competition or cooperation between mixed antibodies can enhance or reduce this protective or harmful effect. Using the laws of chemical reactions, we
arxiv
The receptor-toxin-antibody interaction: Mathematical model and numerical simulation [PDF]
arXiv, 2012 A reaction-diffusion model of receptor-toxin-antibody (RTA) interaction is studied numerically. The protective properties of an antibody against a given toxin are evaluated for a spherical cell placed into a toxin-antibody solution. The selection of parameters for numerical simulation approximately corresponds to the practically relevant values ...
arxiv
Fc receptors for IgG (Fc gamma Rs) on human monocytes and macrophages are not infectivity receptors for human immunodeficiency virus type 1 (HIV-1): studies using bispecific antibodies to target HIV-1 to various myeloid cell surface molecules, including the Fc gamma R. [PDF]
, 1991 Ruth I. Connor +5 more
openalex +1 more source
Clinical Pharmacology &Therapeutics, EarlyView.All biotherapeutics have the potential to induce an immunogenic response and generate anti‐drug antibodies (ADAs), especially when administered as multiple doses over prolonged periods. However, a clinically meaningful effect of ADAs can be difficult to identify to communicate the impact of immunogenicity on drug exposure, safety and efficacy outcomes ...
Susan Richards +13 more
wiley +1 more source
Frontiers in PharmacologyOver the past 2 decades, tumor immunotherapies have witnessed remarkable advancements, especially with the emergence of immune checkpoint-targeting bispecific antibodies.
Yiyang Xu +9 more
doaj +1 more source
Model‐Informed Drug Development Applications and Opportunities in mRNA‐LNP Therapeutics
Clinical Pharmacology &Therapeutics, EarlyView.The utilization of lipid nanoparticles (LNP) for encapsulating mRNA has revolutionized the field of therapeutics, enabling the rapid development of COVID‐19 vaccines and cancer vaccines. However, the clinical development of mRNA‐LNP therapeutics faces numerous challenges due to their complex mechanisms of action and limited clinical experience.
Jiawei Zhou +6 more
wiley +1 more source
Treatment of Refractory Hodgkin's Disease With an Anti-CD16/CD30 Bispecific Antibody [PDF]
, 1997 Frank Hartmann +7 more
openalex +1 more source
A pivotal decade for bispecific antibodies?
mAbsBispecific antibodies (bsAbs) are a class of antibodies that can mediate novel mechanisms of action compared to monospecific monoclonal antibodies (mAbs). Since the discovery of mAbs and their adoption as therapeutic agents in the 1980s and 1990s, the development of bsAbs has held substantial appeal.
Marlena Surowka, Christian Klein
openaire +3 more sources
Oncology Dose Optimization: Tailored Approaches to Different Molecular Classes
Clinical Pharmacology &Therapeutics, EarlyView.Oncology dose optimization during the era of chemotherapy focused on identifying the maximum tolerated dose (MTD) for registrational trials, often resulting in significant toxicity. The advent of molecular targeted drugs and immunotherapies offers the potential to achieve similar efficacy with lower doses and fewer side effects, as maximal efficacy is ...
Jiawen Zhu +12 more
wiley +1 more source